SCHEMBL2902826

SCHEMBL2902826

CN(C)C(Cl)=[N+](C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Iodide SCHEMBL7629995 0.97
Hydrochloric Acid SCHEMBL2266459 0.97
SCHEMBL3113482 0.88 ALDH1A1 (0.32)
Thiocyanic Acid SCHEMBL5096236 0.84
SCHEMBL17514043 0.82 ALDH1A1 (0.33)
SCHEMBL5099958 0.82
Trifluoromethanesulfonic Acid SCHEMBL5102952 0.75
SCHEMBL9344784 0.65 ALDH1A1 (0.33)
SCHEMBL5322556 0.62
SCHEMBL627736 0.62

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 285 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3862431-B1 METHOD FOR PRODUCING HAIRPIN SINGLE-STRAND RNA MOLECULES TORAY INDUSTRIES (JP) 2024-06-26 EP claimed
EP-3953334-B1 NOVEL SYNTHETIC OPTIONS TOWARDS THE MANUFACTURE OF (6R,10S)-10- {4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)- PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15 -(METHENO)PYRAZOLO [4,3-B] [1,7] DIAZACYCLOTETRADECIN-5(6H)-ONE BRISTOL MYERS SQUIBB CO (US) 2023-11-22 EP claimed
EP-3087093-B1 PHARMACEUTICALLY RELEVANT AROMATIC-CATIONIC PEPTIDES STEALTH BIOTHERAPEUTICS CORP (MC) 2021-11-10 EP claimed
EP-3110828-B1 CONTINUOUS FLOW PEPTIDE SYNTHESIS UNIV SZEGEDI (HU) 2020-12-09 EP claimed
EP-0439745-B1 Process for the preparation of 2-chloro-5-methyl-pyridine BAYER AG (DE) 1994-08-03 EP claimed
EP-4747248-A1 COMPOUNDS FOR USE IN A METHOD OF TARGETED PROTEIN DEGRADATION Institute of Cancer Research: Royal Cancer Hospital (The) (GB) 2026-05-27 EP disclosed
US-20260138998-A1 GLP-1 RECEPTOR AGONISTS AND METHODS OF USE MERCK SHARP & DOHME LLC (US) 2026-05-21 US disclosed
US-12630510-B2 EP2 antagonist ONO PHARMACEUTICAL CO., LTD. (JP) 2026-05-19 US disclosed
WO-2026098519-A1 RADIOLIGAND COMPOUNDS AND USES THEREOF Chengdu New Radiomedicine Technology Co., Ltd. (CN) 2026-05-15 WO disclosed
US-20260132158-A1 PHENYL OXY AMIDE KINASE INHIBITORS THE TRANSLATIONAL GENOMICS RESEARCH INST (US) 2026-05-14 US disclosed
WO-2025098391-A9 SELECTIVE DRUG RELEASE FROM CONJUGATES OF BIOLOGICALLY ACTIVE COMPOUNDS NONA BIOSCIENCES (SUZHOU) CO., LTD. (CN) 2026-04-30 WO disclosed
EP-3886904-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-04-22 EP disclosed
US-20090270402-A1 Novel triazolopyridazines ABBVIE INC. 2009-10-29 US disclosed
US-20090004753-A1 LABELING REAGENTS AND METHODS OF THEIR USE INVITROGEN CORPORATION (US) 2009-01-01 US disclosed
US-7439395-B2 Process for the preparation of guanidinium salts MERCK PATENT GMBH (DE) 2008-10-21 US disclosed
US-20070135645-A1 Process for the preparation of guanidinium salts MERCK PATENT GMBH (DE) 2007-06-14 US disclosed
EP-0869940-B1 METHOD FOR PREPARING ORGANIC DISULPHIDES AND POLYSULPHIDES IN THE PRESENCE OF POLYSTYRENE-DIVINYLBENZENE (PS-DVB) RESINS HAVING GUANIDINE OR AMIDINE GROUPS ELF AQUITAINE (FR) 2000-04-05 EP disclosed
WO-1997021740-A1 METHOD FOR PREPARING RESINS HAVING A PRIMARY AMINE OR GUANIDINE FUNCTION, AND RESULTING RESINS ELF AQUITAINE PRODUCTION (FR) 1997-06-19 WO disclosed
EP-0268507-B1 PROCESS FOR THE PREPARATION OF ALKYLTHIOCHLOROFORMIATES SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) 1991-03-06 EP disclosed
EP-0268507-A1 Process for the preparation of alkylthiochloroformiates SOCIETE NATIONALE DES POUDRES ET EXPLOSIFS (FR) 1988-05-25 EP disclosed